End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
994 KRW | +8.52% | -.--% | -80.70% |
03-29 | CANARIABIO Inc.(KOSDAQ:A016790) dropped from S&P Global BMI Index | CI |
01-24 | Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis | MT |
Sales 2022 | 158B 114M 9.02B | Sales 2023 | 161B 116M 9.16B | Capitalization | 927B 668M 52.9B |
---|---|---|---|---|---|
Net income 2022 | -283B -204M -16.13B | Net income 2023 | -208B -150M -11.88B | EV / Sales 2022 | 4.42 x |
Net Debt 2022 | 118B 84.63M 6.71B | Net Debt 2023 | 106B 76.36M 6.05B | EV / Sales 2023 | 6.43 x |
P/E ratio 2022 |
-1.62
x | P/E ratio 2023 |
-3.87
x | Employees | 78 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.65% |
1 day | +8.52% | ||
6 months | -80.04% | ||
Current year | -80.70% |
Managers | Title | Age | Since |
---|---|---|---|
Han-Ik Na
CEO | Chief Executive Officer | 48 | 16/06/22 |
Young-Sik Hong
BRD | Director/Board Member | 66 | - |
Ji-Yeon Lee
AUD | Comptroller/Controller/Auditor | 41 | 16/06/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 82 | - | |
Hyun-Wook Moon
BRD | Director/Board Member | 52 | 16/06/22 |
Young-Sik Hong
BRD | Director/Board Member | 66 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
1st Jan change | Capi. | |
---|---|---|
-80.70% | 135M | |
+2.96% | 10.54B | |
-1.07% | 5.73B | |
+18.37% | 5.18B | |
+1.00% | 5.07B | |
-32.55% | 2.28B | |
-0.90% | 1.83B | |
-28.13% | 1.05B | |
+43.35% | 978M | |
-26.53% | 847M |
- Stock Market
- Equities
- A016790 Stock